The Clorox Company (NYSE:CLX) Shares Sold by Banque Cantonale Vaudoise

Banque Cantonale Vaudoise cut its stake in shares of The Clorox Company (NYSE:CLX - Free Report) by 29.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 23,598 shares of the company's stock after selling 9,935 shares during the period. Banque Cantonale Vaudoise's holdings in Clorox were worth $3,844,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Mizuho Securities USA LLC increased its holdings in Clorox by 46,877.8% in the 3rd quarter. Mizuho Securities USA LLC now owns 4,500,000 shares of the company's stock worth $733,095,000 after acquiring an additional 4,490,421 shares in the last quarter. Van ECK Associates Corp raised its position in shares of Clorox by 1,715.5% during the 2nd quarter. Van ECK Associates Corp now owns 1,461,207 shares of the company's stock valued at $199,411,000 after purchasing an additional 1,380,724 shares during the period. Nuance Investments LLC lifted its stake in shares of Clorox by 150.6% during the 2nd quarter. Nuance Investments LLC now owns 1,597,674 shares of the company's stock valued at $218,035,000 after buying an additional 960,094 shares in the last quarter. Wulff Hansen & CO. boosted its holdings in Clorox by 13,547.0% in the 2nd quarter. Wulff Hansen & CO. now owns 440,116 shares of the company's stock worth $60,063,000 after buying an additional 436,891 shares during the period. Finally, International Assets Investment Management LLC increased its stake in Clorox by 424.9% in the 3rd quarter. International Assets Investment Management LLC now owns 538,576 shares of the company's stock worth $877,390,000 after buying an additional 435,971 shares in the last quarter. Institutional investors own 78.53% of the company's stock.

Insider Activity

In related news, EVP Angela C. Hilt sold 1,733 shares of the business's stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $165.52, for a total value of $286,846.16. Following the completion of the sale, the executive vice president now owns 13,471 shares in the company, valued at approximately $2,229,719.92. The trade was a 11.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.57% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on CLX shares. DA Davidson upped their price objective on Clorox from $153.00 to $171.00 and gave the stock a "neutral" rating in a research note on Monday, November 4th. Jefferies Financial Group raised shares of Clorox from a "hold" rating to a "buy" rating and increased their price objective for the company from $174.00 to $187.00 in a report on Tuesday, October 1st. Deutsche Bank Aktiengesellschaft upped their target price on shares of Clorox from $144.00 to $151.00 and gave the stock a "hold" rating in a research report on Friday, August 2nd. TD Cowen upgraded shares of Clorox from a "sell" rating to a "hold" rating and boosted their price target for the stock from $155.00 to $170.00 in a research note on Wednesday, November 6th. Finally, JPMorgan Chase & Co. raised their price objective on Clorox from $148.00 to $174.00 and gave the company a "neutral" rating in a research report on Friday, October 11th. Five analysts have rated the stock with a sell rating, ten have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Clorox presently has a consensus rating of "Hold" and a consensus price target of $155.00.

Clorox Trading Down 0.1 %

Shares of CLX stock traded down $0.09 during trading hours on Wednesday, reaching $168.05. 1,131,294 shares of the stock were exchanged, compared to its average volume of 1,243,088. The firm has a market capitalization of $20.80 billion, a price-to-earnings ratio of 58.59, a price-to-earnings-growth ratio of 3.10 and a beta of 0.41. The Clorox Company has a 12-month low of $127.60 and a 12-month high of $169.21. The company's 50-day moving average price is $162.56 and its 200-day moving average price is $147.94. The company has a current ratio of 1.00, a quick ratio of 0.62 and a debt-to-equity ratio of 11.08.

Clorox (NYSE:CLX - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.50. Clorox had a net margin of 4.78% and a return on equity of 316.08%. The business had revenue of $1.76 billion during the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter last year, the firm earned $0.49 earnings per share. The firm's quarterly revenue was up 27.0% compared to the same quarter last year. As a group, equities analysts anticipate that The Clorox Company will post 6.85 earnings per share for the current year.

Clorox Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 29th will be given a dividend of $1.22 per share. The ex-dividend date of this dividend is Wednesday, January 29th. This represents a $4.88 annualized dividend and a dividend yield of 2.90%. Clorox's dividend payout ratio (DPR) is 170.04%.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.